MOLLY PAK: Open Payments
NPI 1588027304 · MOUNT LAUREL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,522 in 42 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,522
Food & beverage: $1,522
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $258 |
| ABBVIE INC. | 3 | $250 |
| Ardelyx, Inc. | 11 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $184 |
| GENZYME CORPORATION | 6 | $178 |
| Janssen Biotech, Inc. | 1 | $142 |
| Celltrion USA Inc. | 1 | $123 |
| Lilly USA, LLC | 1 | $107 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
Products named: XIFAXAN, IBSRELA, DUPIXENT, TREMFYA, ENTYVIO, ZYMFENTRA, ZEPBOUND, GATTEX.
Industry payments across NJ — which companies pay providers there.
